Indraprastha Medical Corporation Limited has informed the Exchange about General Updates
INDRAMEDCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Indraprastha Medical Corporation (Indraprastha Apollo Hospitals) approved unaudited Q1 FY26 results showing revenue from operations of Rs 365.06 crore, up about 5% from Rs 347.86 crore in Q1 FY25. Profit after tax rose roughly 15% YoY to Rs 51.46 crore versus Rs 44.77 crore, with EPS at Rs 5.61 (vs Rs 4.88). Total income stood at Rs 371.96 crore and profit before tax at Rs 68.31 crore. Mr. Sudhir Jalan, former FICCI and ICC India President, was appointed as Independent Director for 5 years effective August 6, 2025, subject to shareholder approval. The 37th AGM is fixed for September 24, 2025, with the record date set as September 18, 2025, for determining shareholders eligible for the FY25 dividend. Cost Auditors (M/s Devarajan Swaminathan and Co.) were re-appointed for FY25-26, and M/s RSM & Co. appointed as Secretarial Auditors for five years from FY25-26 to FY29-30.
Solid double-digit profit growth and steady revenue expansion in Q1 FY26 are positive for shareholders. Investors buying before September 18, 2025 will be eligible for the FY25 dividend. The new Independent Director brings strong industry and chamber-of-commerce experience, strengthening board oversight.